Aurelio Sonzogni

Aurelio Sonzogni

Auto-generated profile, based on publicly available information

Aurelio Sonzogni

Department of Pathology, ASST Bergamo Est, Seriate, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2020 in Liver International
Verified
Journal Article
Closed access
ASAurelio Sonzogni
Aurelio Sonzogni
GPGiulia Previtali
Giulia Previtali
MSMichela Seghezzi
Michela Seghezzi
MAMaria Grazia Alessio
Maria Grazia Alessio
AGANDREA GIANATTI
ANDREA GIANATTI
MNManuela Nebuloni
Manuela Nebuloni

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
MMMatthew J. McConnell
Matthew J. McConnell
NKNao Kawaguchi
Nao Kawaguchi
RKReiichiro Kondo
Reiichiro Kondo
ASAurelio Sonzogni
Aurelio Sonzogni
LLLisa Licini
Lisa Licini
YIYasuko Iwakiri
Yasuko Iwakiri

1 November 2022 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
MBMattia Busana
Mattia Busana
CZCarmelo Zinnato
Carmelo Zinnato
FRFederica Romitti
Federica Romitti
MPMichela Palumbo
Michela Palumbo
SGSimone Gattarello
Simone Gattarello
LGLuciano Gattinoni
Luciano Gattinoni
The amount of energy delivered to the respiratory system is recognized as a cause of Ventilator Induced Lung Injury (VILI). How energy dissipation within the lung causes damage is still a matter of debate. Expiratory flow control has been proposed as a strategy to reduce the energy dissipated into the respiratory system during expiration and, possibly, VILI. We studied 22 healthy pigs (29±2 kg), which were randomized into a control (n=11) and a valve group (n=11), where the expiratory flow was controlled through a variable resistor. Both groups were ventilated with the same tidal volume, PEEP and inspiratory flow. Electric impedance tomography was continuously acquired. At completion, lung weight, wet to dry ratios and histology were evaluated. The total mechanical power was similar in the control and valve groups (8.54±0.83 J min-1 and 8.42±0.54 J min-1 respectively, p=0.552). The total energy dissipated within the whole system (circuit + respiratory system) was remarkably different (4.34±0.66 vs 2.62±0.31 J/min, p<0.001). However, most of this energy was dissipated across the endotracheal tube (2.87±0.3 vs 1.88±0.2 J/min, p<0.001). The amount dissipated into the respiratory system averaged 1.45±0.5 in controls vs 0.73±0.16 J min-1 in the valve group, p<0.001. Although respiratory mechanics, gas exchange, hemodynamics, wet to dry ratios and histology were similar in the two groups, the decrease of end-expiratory lung impedance was significantly greater in the control group (p=0.02). We conclude that with our experimental conditions, the reduction of energy dissipated in the respiratory system did not lead to appreciable differences in VILI.

1 April 2021 in European Journal of Radiology
Verified
Journal Article
Closed access
VCValle Clarissa
Valle Clarissa
Pietro Andrea BonaffiniPietro Andrea Bonaffini
Pietro Andrea Bonaffini
MCM. Dal Corso
M. Dal Corso
EMElisa Mercanzin
Elisa Mercanzin
PFPaolo Niccolò Franco
Paolo Niccolò Franco
SSS. Sironi
S. Sironi

20 June 2024 in Journal of Hepatology
Verified
Journal Article
Open access
MCMassimiliano Cadamuro
Massimiliano Cadamuro
ALAlberto Lasagni
Alberto Lasagni
CRClaudia Maria Radu
Claudia Maria Radu
ACArianna Calistri
Arianna Calistri
MPMatteo Pilan
Matteo Pilan
LFLuca Fabris
Luca Fabris
Mechanisms and clinical impact of portal microthrombosis featuring severe COVID-19 are unknown. Intrapulmonary vascular dilation (IPVD)-related hypoxia has been described in severe liver diseases. We hypothesized that portal microthrombosis is associated with IPVD and fatal respiratory failure in COVID-19. Ninety-three patients who died from COVID-19, were analysed for portal microvascular damage (histology), IPVD (histology and chest-computed tomography, CT), and hypoxemia (arterial blood gas). Seventeen patients who died from COVID-19-unrelated pneumonia served as controls. Vascular lesions and microthrombi were phenotyped for endothelial (vWF) and pericyte (αSMA/PDGFR-β) markers, tissue factor (TF), viral spike-protein and nucleoprotein (SP, NP), fibrinogen, platelets (CD41a). Viral particles in vascular cells were assessed by transmission electron microscopy (TEM). Cultured pericytes were infected with SARS-CoV-2 to measure TF expression and tubulisation of human pulmonary microvascular endothelial cells (HPMEC) was assessed upon vWF treatment. IPVD was present in 16/66 COVID-19 patients with both liver and lung histology, with a younger age (62 vs 78yo), longer illness (25 vs 14 days), worsening hypoxemia (PaO2/FiO2 from 209 to 89), and more ventilatory support (63 vs 22%) compared to COVID-19/Non-IPVD. IPVD, absent in controls, were confirmed by chest-CT. COVID-19/IPVD liver histology showed portal microthrombosis in >82.5% of portal areas, with a thicker wall of αSMA/PDGFR-β+/ SP+/NP+ pericytes compared with COVID-19/Non-IPVD. Thrombosed portal venules correlated with αSMA+ area, whereas infected SP+/NP+ pericytes expressed TF. SARS-CoV-2 viral particles were observed in portal pericytes. In-vitro SARS-CoV-2 infection of pericytes up-regulated TF and induced endothelial cells to overexpress vWF, which expanded HPMEC tubules. SARS-CoV-2 infection of liver pericytes elicits a local procoagulant response associated with extensive portal microthrombosis, IPVD and worsening respiratory failure in fatal COVID-19. Vascular involvement of the liver represents a serious complication of COVID-19 infection that must be considered in the work-up of patients with long-lasting and progressively worsening respiratory failure, as it may associate with the development of intrapulmonary vascular dilations. This clinical picture is associated with a pro-coagulant phenotype of portal venule pericytes, which is induced by SARS-CoV-2 infection of pericytes. Both observations provide a model that may apply, at least in part, to other vascular disorders of the liver, featuring obliterative portal venopathy, similarly characterized at the clinical level by development of hypoxemia and at the histological level, by phlebosclerosis and reduced caliber of the portal vein branches in the absence of cirrhosis. Moreover, our findings bring light to an as yet overlooked player of thrombosis pathophysiology, i.e. pericytes, which may provide novel therapeutic tools to halt prothrombotic mechanisms.

1 November 2004 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
DADaniele Alberti
Daniele Alberti
ABAlessandro Borsellino
Alessandro Borsellino
LMLucia Migliazza
Lucia Migliazza
MBMario Leo Brena
Mario Leo Brena
ASAurelio Sonzogni
Aurelio Sonzogni
GLGiuseppe Locatelli
Giuseppe Locatelli